Weizmann Born Prostate Cancer Therapy in Advanced Trials

A new prostate cancer drug called Tookad®, which is currently approved in Mexico for early–stage treatment, is now undergoing advanced trials in Israel and Europe, with European approval hoped for soon.

The novel therapy is delivered by injection and activated using laser light, with the idea of applying light in cancer therapy born in Weizmann Institute of Science laboratories by Professors Yoram Saloman and Avigdor Sherz.

The drug is based on the action of bacteriochlorophyll a compound used by types of aquatic bacteria to make energy from the sun via photosynthesis.  In this case, the synthetic compound that comprises Tookad® is injected into the patient and quickly followed by near-infrared laser illumination delivered via thin optic fibres, inserted into the cancerous region.

Once in the body the light activates the drug which releases short-lived oxygen and nitric oxide radicals designed to restrict and destroy a tumour’s blood supply.  This is done in such a way that healthy tissue is not affected. After 90 minutes the drug is clear of the body and within a few days the patient is fully recovered.

CEO of Weizmann’s technology transfer arm – Yeda Research and Development Company – Mr Amir Naiberg, said the minimally invasive treatment was a positive alternative for patients with early diagnosed prostate cancer.

“The number of these patients has dramatically increased in the last two decades due to widespread screening relying on levels of prostate specific antigen (PSA). This population faces the dilemma of undergoing the radical treatment of prostate removal with the risk of high morbidity, or remaining under active surveillance with increased risk of further cancer progression,” he said.

Yeda worked with Steba Biotech to develop the drug and activation system which was ultimately licensed to Sreba by Yeda once the process was finalised.

Mexico was swift to approve the drug following a successful first Phase III clinical trial of 80 patients in Mexico and a second in Europe, both confirming a high rate of localised cures and minimal side-effects reported in previous phase II trials.  This was evidenced with negative biopsies plus patients’ quality of life, potency and continence.

An application for market approval in Europe using Tookad™® to treat localised prostate cancer is currently underway.

Its use in more advanced prostate cancer and other cancers – esophageal cancer, urothelial carcinoma, renal carcinoma and triple-negative breast cancer – is also taking place in four clinical studies at Oxford University, Memorial Sloan Kettering Cancer Center in New York City, and Assuta Hospital, Tel Aviv.

Tookad® is not yet approved in Australia and the Therapeutic Goods Association cannot confirm or deny if an application has been made. We will keep you informed of progress.

Share this article

Latest news

Sensing Fat

Sensing Fat

New research from the Weizmann Institute of Science reveals that the nervous system can sense fat tissue and that blocking this ability protects mice from metabolic disorders. Popular belief holds that our senses gather information only about the external world, but...

Food: Friend, Not Foe – New Study Explains Why

Food: Friend, Not Foe – New Study Explains Why

Weizmann Institute of Science researchers have revealed the cellular network behind oral tolerance, the immune mechanism that enables us to eat food safely.  If we have an allergy to peanuts, strawberries or dairy, we are quick to blame our immune systems. But...

MRI Gets a Nano-Sized Upgrade

MRI Gets a Nano-Sized Upgrade

Weizmann Institute of Science researchers have achieved an MRI resolution of one billionth of a metre, paving the way for the most detailed images of individual molecules ever produced. This new development will play a major role in the materials and pharmaceutical...

Beyond Words

Beyond Words

Weizmann Institute researchers have revealed that the melody of spoken English functions as a distinct language, with a vocabulary and rules of syntax.  The findings lay the foundation for an AI that will understand language beyond just words. The AI revolution, which...

All embroidery colours

All embroidery colours

AI-based technology developed in Dr Liat Keren's lab at the Weizmann Institute of Science has shown it enables an unprecedented view of processes in body tissues. Artificial intelligence systems are working magic in many areas of the life sciences – they help decipher...